Inflammatory bowel disease: Part II. Medical and surgical management.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 8438680.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Substantial advances have been made in the management of inflammatory bowel disease. Mesalamine and olsalazine are new anti-inflammatory agents that may serve as alternatives to corticosteroids and sulfasalazine, which have been the mainstays of medical therapy. These new agents are available in oral, enema and suppository forms. Brooke ileostomy remains the standard surgical treatment for advanced ulcerative pancolitis, but continent ileostomy procedures may be more cosmetically acceptable to selected patients.